AstraZeneca: Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients With Limited-Stage Small Cell Lung Cancer
December 06, 2024
December 06, 2024
WILMINGTON, Delaware, Dec. 6 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo
* * *
AstraZeneca's IMFINZI (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent p . . .
* * *
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo
* * *
AstraZeneca's IMFINZI (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent p . . .